CXCR4 antagonists (e.g., plerixafor) modulate tumour microenvironment (TME) dynamics by disrupting the CXCR4/CXCL12 chemotactic axis, thereby impeding metastatic niche colonisation through interference with tumour cell tropism. The gene discussed is CXCR4; the disease is neoplasm.